Neuropsychological impairment among asymptomatic HIV-positive former intravenous drug users

Cognitive and Behavioral Neurology

Volumn 19, Issue 2, 2006, Pages 95-104

  Rodriguez Salgado D ^a   Rodriguez Alvarez M ^a   Seoane Pesqueira, G ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Abstinence; Drug user; Human immunodeficiency virus infection; Methadone; Neuropsychological impairment

Indexed keywords

ANTIRETROVIRUS AGENT; DIAMORPHINE; METHADONE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; EDUCATION; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METHADONE TREATMENT; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SPAIN; VIRUS LOAD;

ADULT; CHI-SQUARE DISTRIBUTION; HETEROSEXUALITY; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MENTAL DISORDERS; METHADONE; NARCOTICS; NEUROPSYCHOLOGICAL TESTS; SPAIN; STATISTICS, NONPARAMETRIC; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33745320976     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnn.0000182832.54697.5c     Document Type: Article

References (96)

1. Gapen P. Neurological complications now characterizing many AIDS victims. JAMA. 1982;248:2941-2942.
2. Loewenstein RJ, Sharfstein SS. Neuropsychiatric aspects of acquired immune deficiency syndrome. Int J Psychiatry Med. 1983;13:255-260.
3. Snider WD, Simpson DM, Nielsen S, et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983;14:403-418.
4. World Health Organization. Report of the Second Consultation on the Neuropsychiatric Aspects of HIV-1 Infection. Paper presented at the Global Programme on AIDS, Geneva, Switzerland; 1990.
5. Grant I, Martin A. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994.
6. Heaton RK, Grant I, Butters N, et al, The HNRC 500-Neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc. 1995;1:231-251.
7. McArthur JC, Grant I. HIV neurocognitive disorders. In: Gendelman HE, Lipton SA, Epstein L, et al. eds. In: The Neurology of AIDS. New York: Chapman & Hall; 1998:499-523.
8. Marcotte TD, Grant I, Atkinson JH, et al. Neurobehavioural complications of HIV infection. In: Tarter RE, Butters M, Beers SR, eds. Medical Neuropsychology. Clinical Issues in Neuropsychology. New York: Kluwer Academic/Plenum Publishers; 2001:285-331.
9. Newman SP, Lunn S, Harrison JG. Do asymptomatic HIV-seropositive individuals show cognitive deficit? AIDS. 1995;9:1211-1220.
10. White DA, Heaton RK, Monsch AU, et al. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. J Int Neuropsychol Soc. 1995;1:304-315.
11. Basso MR, Bornstein RA. Neurobehavioural consequences of substance abuse and HIV infection. J Psychopharmacol. 2000;14:228-237.
12. Shor-Posner G. Cognitive function in HIV-1-infected drug users. J Acquir Immune Defic Syndr. 2000;25(Suppl 1):70-73.
13. Silberstein CH, McKegney FP, O'Dowd MA, et al. A prospective longitudinal study of neuropsychological and psychosocial factors in asymptomatic individuals at risk of HTLV-III/LAV infection in a methadone program: Preliminary findings. Int J Neurosci. 1987;32:669-676.
14. McKegney FP, O'Dowd MA, Feiner C, et al. A prospective comparison of neuropsychologic function in HIV-seropositive and seronegative methadone-maintained patients. AIDS. 1990;4:565-569.
15. Royal W III, Updike M, Selnes OA, et al. HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users. Neurology. 1991;41:1905-1910.
16. Sinforiani E, Mauri M, Bono G, et al. Cognitive abnormalities and disease progression in a selected population of asymptomatic HIV-positive subjects. AIDS. 1991;5:1117-1120.
17. Handelsman L, Aronson M, Maurer G, et al. Neuropsychological and neurological manifestations of HIV-1 dementia in drug users. J Neuropsychiatry Clin Neurosci. 1992;4:21-28.
18. Marder K, Stern Y, Malouf R, et al. Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome. Arch Neurol. 1992;49:1169-1175.
19. Del Pesce M, Franciolini B, Censori B, et al. Cognitive behavior in asymptomatic (CDC stage II and III) HIV-seropositive intravenous drug users (IVDUs). Ital J Neurol Sci. 1993;17:619-625.
20. Egan V, Deary IJ, Brettle RP. The Edinburgh cohort of HIV-positive drug users: the effects of depressed mood and drug use upon neuropsychological function. Br J Health Psychol. 1996;1:231-244.
21. Stern Y, Liu X, Marder K, et al. Neuropsychological changes in a prospectively followed cohort of intravenous drug users with and without HIV. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:83-90.
22. Starace F, Baldassarre C, Biancolilli V, et al. Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand. 1998;97:132-138.
23. Ayuso-Mateos JL, Pereda M, Gómez del Barrio A, et al. Slowed reaction time in HIV-1-seropositive intravenous drug users without AIDS. Eur Neurol. 2000;44:72-77.
24. Farinpour R, Martin EM, Seidenberg M, et al. Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc. 2000;6:548-555.
25. Egan V, Crawford JR, Brettle RP, et al. The Edinburgh cohort of HIV-positive drug users: current intellectual function is impaired, but not due to early AIDS dementia complex. AIDS. 1990;4:651-656.
26. Cappa SF, Truong TM, Vangi D, et al. The neuropsychological consequences of HIV infection in drug addicts. Ital J Neurol Sci. 1992;13:465-468.
27. Concha M, Graham NMH, Muñoz A, et al. Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. Am J Epidemiol. 1992;136:1338-1348.
28. Wellman MC. Neuropsychological impairment among intravenous drug users in pre-AIDS stages of HIV infection. Int J Neurosci. 1992;64:183-194.
29. Hestad K, Aukrust P, Ellertsen B. Neuropsychological deficits in HIV-1 seropositive and seronegative intravenous drug users. J Clin Exp Neuropsychol. 1993;15:732-742.
30. 2 microglobulin and CD4 counts to neuropsychological performance in HIV-1-infected intravenous drug users. J Acquir Immune Defic Syndr. 1994;7:1040-1049.
31. Grassi MP, Clerici F, Perin C, et al. HIV infection and drug use: Influence on cognitive function. AIDS. 1995;9:165-170.
32. Bono G, Mauri M, Sinforiani E, et al. Longitudinal neuropsychological evaluation of HIV-infected intravenous drug users. Addiction. 1996;91:263-268.
33. Wilkins JW, Robertson KR, Van Der Horst C, et al. The importance of confounding factors in the evaluation of neuropsychological changes in patients infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3:938-942.
34. Van Gorp WG, Lamb DG, Schmitt FA. Methodologic issues in neuropsychological research with HIV-spectrum disease. Arch Clin Neuropsychol. 1993;8:17-33.
35. Stern Y. Neuropsychological assessment of seropositive intravenous drug users. In: Grant I, Martin A, eds. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994:220-233.
36. Vázquez-Justo E, Rodríguez-Álvarez M. Influencia de factores no relacionados con la infección en el rendimiento neuropsicológico de seropositivos al VIH. Rev Neurol. 2002;35:474-480.
37. Rodríguez Álvarez M, Rodríguez Salgado D. Estudio de la afectación neuropsicológica asociada al VIH: Revisión de aspectos metodológicos. Actas Esp Psiquiatr. 2003;31:79-84.
38. Zacny JP. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp Clin Psychopharmacol. 1995;3:432-466.
39. Selby MJ, Azrin RL. Neuropsychological functioning in drug abusers. Drug Alcohol Depend. 1998;50:39-45.
40. Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol. 2001;11:250-257.
41. Appel PW, Gordon NB. Digit-symbol performance in methadone-treated ex-heroin addicts. Am J Psychiatry. 1976;133:1337-1340.
42. Darke S, Sims J, McDonald S, et al. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95:687-695.
43. Specka M, Finkbeiner Th, Lodemann E, et al. Cognitive-motor performance of methadone-maintained patients. Eur Addict Res. 2000;6:8-19.
44. Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend. 2002;67:41-51.
45. Gritz ER, Shiffman SM, Jarvik ME, et al. Physiological and psychological effects of methadone in man. Arch Gen Psychiatry. 1975;32:237-242.
46. Davis PE, Liddiard H, McMillan TM. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend. 2002;67:105-108.
47. Pereda M, Ayuso-Mateos JL, Gómez del Barrio A, et al. Factors associated with neuropsychological performance in HIV-seropositive subjects without AIDS. Psychol Med. 2000;30:205-217.
48. Rodríguez Salgado D, Rodríguez Álvarez M. Vulnerabilidad neuropsicológica de los drogodependientes a la infección por VIH-1. Rev Esp Drogodependencias. 1997;22:203-218.
49. American Psychiatric Association. DSM IV Manual diagnóstico y estadístico de los trastornos mentales. Barcelona: Masson; 1995.
50. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
51. Oldfield RC. The assessment and analysis of handedness: The Edinburgh Inventory. Neuropsicologia. 1971;9:97-113.
52. Beck A. Inventario de depresión. Barcelona: Psiké; 1978.
53. Butters N, Grant I, Haxby J, et al. Assessment of AIDS-related cognitive changes: recommendations of the NIMH workshop on neuropsychological assessment approaches. J Clin Exp Neuropsychol. 1990;12:963-978.
54. Maj M, Starace F, Sartorius N. Neuropsychiatric aspects of HIV-1 infection: Data collection instrument for a WHO cross-cultural study. Bull World Health Organ. 1991;69:243-245.
55. Egan V. Neuropsychological aspects of HIV infection. AIDS Care. 1992;4:3-10.
56. Lezak MD. Neuropsychological Assessment. New York: Oxford University Press; 1995.
57. Wechsler D. Escala de Inteligencia de Wechsler para adultos. Madrid: TEA; 1995.
58. Rey A. L'examen Clinique en Psychologie. Paris: Presses Universitaires; 1964.
59. Trenerry MR, Crosson B, Deboe J, et al. Visual Search and Attention Test. Florida: Psychological Assessment Resources; 1990.
60. Reitan RM. Trail Making Test. Manual for Administration and Scoring. Tucson: Reitan Neuropsychology Laboratory; 1992.
61. Benton AL, Hamsher KS. Multilingual Aphasia Examination. Iowa City: University of Iowa; 1978.
62. Benton AL. Test de retención visual de Benton. Madrid: TEA; 1981.
63. Kaplan E, Goodglass H, Weintraub S. Test de Vocabulario de Boston. Madrid: Editorial Médica Panamericana; 1986.
64. Golden CJ. Test de colores y palabras Stroop. Madrid: TEA; 1994.
65. Tiffin J. Purdue Pegboard. Lafayette, IN: Lafayette Instrument; 1948.
66. Rey A. Test de copia de una figura compleja. Madrid: TEA; 1987.
67. Reitan RM. Finger Tapping Test. Tucson: Reitan Neuropsychology Laboratory; 1979.
68. Heaton RK, Chelune GJ, Talley JL, et al. Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993.
69. Spss, Inc. SPSS para Windows, versión 9.0.1. Chicago: SPSS; 1999.
70. Bornstein RA. Methodological and conceptual issues in the study of cognitive change in HIV infection. In: Grant I, Martin A, eds. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994:146-160.
71. Heseltine PNR, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55:41-51.
72. Margolin A, Avants SK, Warburton LA, et al. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care STDS. 2002;16:255-267.
73. Grassi MP, Perin C, Clerici F, et al. Neuropsychological performance in HIV-1 infected drug abusers. Acta Neurol Scand. 1993;88:119-122.
74. Bornstein RA, Nasrallah HA, Para MF, et al. Neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci. 1992;4:386-394.
75. Vázquez-Justo E, Rodríguez Alvarez M, Carro Ramos J. Neuropsychological performance in HIV/AIDS intravenous drug users. J Clin Exp Neuropsychol. 2003;25:852-865.
76. De Ronchi D, Faranca I, Berardi D, et al. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Arch Neurol. 2002;59:812-818.
77. Rodríguez Álvarez M, Vázquez-Justo E. Influencia de factores relacionados con la infección en el rendimiento neuropsicológico de seropositivos al VIH. Neurologia. 2002;17:328-336.
78. Satz P, Morgenstern H, Miller EN, et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study. AIDS. 1993;6:503-511.
79. Maj M, Satz P, Janssen R, et al. WHO neuropsychiatric AIDS study, cros sectional phase II: neuropsychological and neurological findings. Arch Gen Psychiatry. 1994;51:51-61.
80. Stern RA, Silva SG, Chaisson N, et al. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol. 1996;53:148-153.
81. Elovaara I, Poutianien E, Lähdevirta J, et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch Neurol. 1994;51:943-950.
82. Karlsen NR, Reinvang I, Frøland SS. A follow-up study of neuropsychological functioning in AIDS-patients. Prognostic significance and effect of zidovudine therapy. Acta Neurol Scand. 1995;91:215-221.
83. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol. 1997;42:679-688.
84. Stankoff B, Calvez V, Suárez S, et al. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment. Eur J Neurol. 1999;6:669-675.
85. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002;59:923-928.
86. Bornstein RA, Nasrallah HA, Para MF, et al. Rate of CD4 decline and neuropsychological performance in HIV infection. Arch Neurol. 1991;48:704-707.
87. Boccellari AA, Dilley JW, Chambers DB, et al. Immune function and neuropsychological performance in HIV-1-infected homosexual men. J Acquir Immune Defic Syndr. 1993;6:592-601.
88. Villa G, Monteleone D, Marra C, et al. Neuropsychological abnormalities in AIDS and asymptomatic HIV seropositive patients. J Neurol Neurosurg Psychiatry. 1993;56:878-884.
89. Marder K, Liu X, Stern Y, et al. Neurologic signs and symptoms in a cohort of homosexual men followed for 4,5 years. Neurology. 1995;45:261-267.
90. Becker JT, Sanchez J, Dew MA, et al. Neuropsychological abnormalities among HIV-infected individuals in a community-based sample. Neuropsychology. 1997;11:592-601.
91. Grassi MP, Perin C, Borella M, et al. Assessment of cognitive function in asymptomatic HIV-positive subjects. Eur Neurol. 1999;42:225-229.
92. Carballo-Dieguez A, Sash J, Goetz R. The effect of methadone on immunological parameters among HIV-positive and HIV-negative drug users. Am J Drug Alcohol Abuse. 1994;20:317-329.
93. Quang-Cantagrel ND, Wallace MS, Ashar N, et al. Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. Eur J Pain. 2001;5:415-420.
94. Alonzo NC, Bayer BM. Opioids, immunology and host defenses of intravenous drug abusers. Infect Dis Clin North Am. 2002;16:553-569.
95. Douglas SD. Methadone may promote HIV replication: study. AIDS Alert. 2001;16:120.
96. Li Y, Wang X, Tian S, et al. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis. 2002;185:118-122.